Page 1,078«..1020..1,0771,0781,0791,080..1,0901,100..»

Qatar Foundations Doha Debates Places The Future Of Genetics In The Spotlight – Al-Bawaba

Posted: March 29, 2020 at 4:49 am

The question of where the line should be drawn in human gene editing, and if it should be allowed to create superhumans, has been tackled by Doha Debates in the final debate of the Qatar Foundation productions first season under its new concept.

Three experts participated in an intense discussion on the ethics and challenges of human genetic enhancement during the debate at Northwestern University in Qatar, which, due to the global coronavirus pandemic, was held without its usual live student audience.

But the shows interactive nature and role as a platform for dialogue and discourse was preserved byDoha Debates correspondent Nelufar Hedayat, who videoconferenced with students and shared tweets and Instagram videos from viewers in countries including Nigeria, the UK, Sweden, and Ghana.

The debate primarily focused on germline editing, which results in heritable changes to DNA meaning that, if embryonic DNA was edited to produce blue eyes, the genes for blue eyes would be present in a persons children, and their childrens children and has earned the worlds attention and criticism in recent years. Moderator Ghida Fakhry framed the debate by asking whether the aim of gene editing should be to edit out certain debilitating diseases or conditions, and if it will increase global inequality if it is initially only available to those who can afford it.

Professor Julian Savulescu, an ethicist, moral philosopher and the current Uehiro Chair in Practical Ethics at the University of Oxford, claimed gene editing is a moral imperative for society, saying: What matters to each of us is our overall wellbeing.

We measure that in terms of things like happiness, whether we can set our own goals and achieve them, and whether we have deep and substantial interpersonal relationships. Genes dont just affect health; they also affect our capacity for wellbeing and nature doesnt allocate genes equally.

We already use various biological interventions, like iodizing salt because it improves IQ, removing lead from paint because it causes intellectual disabilities, or using prescription drugs to reduce impulsive violence. Theres no difference between environmental and biological interventions and parents should be able to access these technologies to improve their childrens lives, providing the technologies dont harm their children or other people. Science can tell us how to achieve these things, but ethics can tell us whether we should and the promotion of wellbeing is the central ethical principle.

Technology and health care futurist Jamie Metzl, a member of the Human Genome Project-Write consortium, said gene editing is a foregone conclusion, telling the debate: Were already using so many therapies and technologies to improve the human race, and gene editing is no different.

What if we could engineer people to be resistant to a new coronavirus, or to eradicate painful genetic conditions; improve health care so that its not based on averages of the general population, but customized to your own biology; or allow the human race to live on a planet that will eventually become uninhabitable?

However, he acknowledged the risks of gene editing and their capacity to cause division, saying that in order to avoid deepening inequalities and flattening essential genetic diversity, values and ethics must guide these technologies. The issue of haves and have-nots thats one potential outcome, he said. :If we dont want that outcome, wed better start organizing for a different outcome.

Katie Hasson, the program director on Genetic Justice at the Center for Genetics and Society, asked the online audience: Lets really imagine this world, where each babys DNA is being manipulated from the moment of their conception in the lab, where parents immediate desires are written into their future childrens genome, and the generations to come.

Would the traits perceived as the best be available only to the affluent and privileged? Would gene editing dig deeper trenches between the haves and have-nots? Would parents feel pressured to select traits based on narrowly defined cultural and social norms? These are the questions we need to consider, and now is the time to do so.

The practice is not safe, its not needed, and it has the potential to vastly increase the already outrageous inequality that were experiencing. Instead of using gene editing to level the playing field, intellectually and otherwise, we should work to create a society that values people as they are, with a range of abilities and embodiments.

The post-show segment, hosted by Hedayat, sparked a global conversation, with comments and questions streaming in from Nigeria, Afghanistan, and Poland to Sweden, Brazil, and the US. Hedayat interviewed special guest Nawaal Akram, a Qatari disability rights activist, athlete and comedian. who has the genetic condition muscular dystrophy and said that, for her, this debate was personal.

So much time and research is done for the future, but right now, so many people with disabilities cannot afford the medicine, we cannot afford health care, we cannot afford education, she said.

At three points during the debate, the online audience was asked to score each of the debaters three positions. After the opening statements, Hassons anti-gene editing position garnered the strongest support, with 51 percent. By the end of the debate, support for the middle ground and anti-gene editing position was nearly the same, with Metzl receiving 36 percent and Hasson 38 percent, while Savulescu gained 25 percent.

The debates connector, Dr. Govinda Clayton, asked the speakers to broaden their focus to find some very specific points of agreement. All our speakers, whether they felt wary or energized by the potential of gene editing, agreed on one important point, he said. Its filled with risks and challenges, and we cant build a fairer and more inclusive world without broad agreement on its ethical considerations.

To watch the full debate, including the experts views on editing out diseases like cystic fibrosis, visit http://www.dohadebates.com

Read the original here:
Qatar Foundations Doha Debates Places The Future Of Genetics In The Spotlight - Al-Bawaba

Posted in Human Genetics | Comments Off on Qatar Foundations Doha Debates Places The Future Of Genetics In The Spotlight – Al-Bawaba

More Hints of Order in the Genome – Discovery Institute

Posted: March 29, 2020 at 4:49 am

Genomics has come a long way since the central dogma (the notion that DNA is the master controller that calls all the shots) and junk DNA (the expectation that much of the genome is non-functional). If scientists ditch those old dogmas and approach the genome expecting to find reasons for things, they often do.

To-may-to or to-mah-to? The British write flavour; the Americans write flavor, but generally each understands the other without too much difficulty. Genomes, too, have alternate ways of spelling things: GGU and GGC in messenger RNA both spell glycine. No big deal, thought geneticists; these silent mutations cause no change in the resulting protein. At the University of Notre Dame, however, biochemists are finding that the differences in spelling are not just background noise; they alter the proteins folding. Is that good or bad?

Synonymous mutations were long considered to be genomic background noise, but we found they do indeed lead to altered protein folding, and in turn impair cell function, said Patricia Clark, the Rev. John Cardinal OHara professor of biochemistry at the University of Notre Dame, and lead author of the study. Our results show that synonymous variations in our DNA sequences which account for most of our genetic variation can have a significant impact on shaping the fitness level of cellular proteins.

Surely many of these mutations are harmful, as are random mutations in humans that cause genetic disease. But E. coli has been around for a long time. Wouldnt the species have gone extinct by now with the accumulation of defective spellings if they are always deleterious? Other work has suggested a secret code in synonymous variations that fine-tunes expression rates or regulates the supply of a given protein based on environmental conditions. The news release only mentions impairments caused by synonymous variations, but Notre Dame teams paper in PNAS suggests some possible advantages:

Synonymous codon substitutions alter the mRNA coding sequence but preserve the encoded amino acid sequence. For this reason, these substitutions were historically considered to be phenotypically silent and often disregarded in studies of human genetic variation. In recent years, however, it has become clear that synonymous substitutions can significantly alter protein function in vivo through a wide variety of mechanisms that can change protein level, translational accuracy, secretion efficiency, the final folded structure and posttranslational modifications. The full range of synonymous codon effects on protein production is, however, still emerging, and much remains to be learned regarding the precise mechanisms that regulate these effects. [Emphasis added.]

A design perspective would consider every possible function before rendering a judgment that all synonymous variations reduce fitness.

Keeping the genome accurate to a high degree preserves it from collapsing due to error catastrophe. At the time of cell division, proofreading enzymes (what a concept!) perform this vital function. Chelsea R. Bulock et al., writing in PNAS, have found one duplication enzyme that proofreads itself while proofreading its partner! DNA polymerase proofreads errors made by DNA polymerase , the paper is titled.

Pol and Pol are the two major replicative polymerases in eukaryotes, but their precise roles at the replication fork remain a subject of debate. A bulk of data supports a model where Pol and Pol synthesize leading and lagging DNA strands, respectively. However, this model has been difficult to reconcile with the fact that mutations in Pol have much stronger consequences for genome stability than equivalent mutations in Pol. We provide direct evidence for a long-entertained idea that Pol can proofread errors made by Pol in addition to its own errors, thus, making a more prominent contribution to mutation avoidance. This paper provides an essential advance in the understanding of the mechanism of eukaryotic DNA replication.

In other words, Pol is a proofreader of a proofreader. The paper says that Pol is a versatile extrinsic proofreading enzyme. One could think of it as a supervisor checking the work of a subordinate, or better yet, as an auditor or inspector able to fix errors before they cause harm to the product. Why would this be necessary during replication? The authors see a seniority system:

Thus, the high efficiency of Pol at correcting errors made by Pol may result from a combination of two factors: the high proclivity of Pol to yield to another polymerase and the greater flexibility and robustness of Pol when associating with new primer termini.

One proofreader is amazing to consider evolving by a Darwinian mechanism. A proofreader of a proofreader is astonishing. Consider, too, that this proofreading operation occurs in the dark by feel, automatically, without eyes to see.

Now that genetics is long past the heady days of finding that DNA forms a code that is translated, additional discoveries continue to show additional codes and factors that contribute to genomic function. One factor is the high-order structure of DNA. Researchers at South Koreas UNIST center have explored further into the formation of this structure, which involves chromatin wrapping around histone proteins so that long strands of DNA can fit within the compact space of the cell nucleus. As with everything else in genomics, the structure doesnt just happen. It requires a lot of help.

Regulation of histone proteins allows the DNA strands become more tightly or loosely coiled during the processes of DNA replication and gene expression. However, problems may arise when histones clump together or when DNA strands intertwine. Indeed, the misregulation of chromatin structures could result in aberrant gene expression and can ultimately lead to developmental disorders or cancers.

Histone chaperones are those proteins, responsible for adding and removing specific histones [found] at the wrong time and place during the DNA packaging process. Thus, they also play a key role in the assembly and disassembly of chromatin.

Cryo-EM imaging allowed the team to envision the molecular structure of some of these chaperone proteins. Their paper in Nature Communications begins, The fundamental unit of chromatin, the nucleosome, is an intricate structure that requires histone chaperones for assembly. Their cryo-EM images of one particular chaperone named Abo1 reveals a six-fold symmetry with precise locations for docking to histones, its hexameric ring thus creating a unique pocket where histones could bind with energy from ATP. Not only is Abo1 distinct as a histone chaperone, they write, but Abo1 is also unique compared to other canonical AAA+protein structures. Like Lego blocks, Abo1 features tight knob-and-hole packing of individual subunits plus linkers and other binding sites, such as for ATP. And unlike static blocks, these blocks undergo conformational changes as they work.

Such sophistication is far beyond the old picture of DNA as a master molecule directing all the work. It couldnt work without the help of many precision machines like this.

These stories are mere samples from a vast and growing literature indicating higher order in the genome than expected. Here are some more samples readers may wish to investigate:

Researchers at the University of Seville found additional factors involved in the repair of DNA strand breaks. These repairs are essential for the maintenance of genome integrity. The factors they discovered help maintain the right tension in cohesin molecules that hold the chromosomes together until the right time to separate. The news was relayed by EurekAlert!and published in Nature Communications.

Remember Paleys Watch? Researchers at the University of Basel discovered that Inner clockwork sets the time for cell division in bacteria. In PNAS and in Nature Communications, the Basel team elucidates the structure and function of a small signaling molecule that starts the clock, which then informs the cell about the right time to reproduce. They report in the news release:

A team at the Biozentrum of the University of Basel, led by Prof. Urs Jenal has now identified a central switch for reproduction in the model bacteriumCaulobacter crescentus: the signaling molecule c-di-GMP. In their current study,published in the journalNature Communications,they report that this molecule initiates a clock-like mechanism, which determines whether individual bacteria reproduce.

Proteins must fold properly to perform their functions. Small proteins usually fold successfully on their own, but large ones can fall into several misfolding traps that are equally likely as the canonical fold. It appears that the sequence of the sequence in a gene has something to do with this. Interestingly, many of these proteins sequences contain conserved rare codons that may slow down synthesis at this optimal window, explain Amir Bitran et al. in a January 21 paper in PNAS, discovering that Cotranslational folding (i.e., folding that begins as the polypeptide exits the ribosome) allows misfolding-prone proteins to circumvent deep kinetic traps.

Design advocates and evolutionists need to fathom what they are dealing with when discussing origins. Theres nothing like some low-level detail to put the challenge in perspective.

Image credit: Caulobacter crescentus, by University of Basel, Swiss Nanoscience Institute/Biozentrum, via EurekAlert!

View original post here:
More Hints of Order in the Genome - Discovery Institute

Posted in Human Genetics | Comments Off on More Hints of Order in the Genome – Discovery Institute

The Coronavirus Pandemic Shows Us The Importance Of Combatting Climate Change – Forbes

Posted: March 29, 2020 at 4:49 am

The common fruit fly which lives one to two months, suggesting insignificance has changed the world through medical research, leading to eight Nobel prizes in human genetics and disease prevention breakthroughs. Today an even smaller organism, Coronavirus, is changing the world even more significantly.

And confronting it with the same opportunity for breakthroughs as scientists treated fruit flies could hold the key to solving our greatest challenge climate change.

Of course, all of the coronaviruses impacts sickness, deaths, economic crises have been negative. But, like the scientists who saw something unique in the fruit fly instead of just an unwelcome pest, coronavirus offers us a unique opportunity: visceral lessons in how to approach future crises, and the horrible costs of not doing so.

First among those lessons is taking authoritative warnings seriously, even when that may result in tough decisions. We have been warned repeatedly over the last decade that a pandemic was an existential threat to our way of life. At the end of 2019, when the late Chinese doctor Li Wenliang first reported his alarm over a coronavirus outbreak, authorities detained him for spreading rumors. If they had acted on his warning, the spread in China would have been less severe.

But by January 21, 2020 China had 278 confirmed cases, other countries had 282, and the World Health Organization issued its first coronavirus advisory. Instead of preparing for the virus inevitable spread to the United States, President Donald Trump downplayed the risk, comparing it to a bad case of the flu. Two months later, tens of thousands of Americans have tested positive for the virus and millions more are under shelter-in-place rules, threatening to send the global economy into a devastating tailspin.

Unfortunately, weve consistently made these same mistakes of ignoring scientific warnings when dealing with other global crises, especially climate change. Beginning in June 1988, when climate scientist James Hansen warned Congress that global warming had begun, climate scientists predictions have repeatedly and increasingly warned of impending crises, and how climate change is accelerating faster than expected much like the Coronavirus. Sadly, the government response has ranged from non-existent to lacking.

Thirty years after Hansens warning, President Trump dismissed an official U.S. government assessment of climate changes risks in 2018, saying I dont believe it. As temperatures have risen, so too has the cost of inaction. From 1979 to 2017, the cost of global climate change-related disasters has increased 150%, costing $2.25 trillion, with the U.S. bearing the brunt of the financial pain at $945 billion nearly twice Chinas second-highest total of $492 billion.

Fortunately, in the battle against coronavirus, countries like South Korea that embrace science-based health warnings and act decisively are able to flatten the curve of the coronavirus spread to reduce infections and deaths. But when it comes to climate change, despite global accords such as the Paris Agreement, the world is still struggling to act decisively and in unison.

The Trump administration stands out with its rejection of science-based climate change policy, compounding decades of foot dragging by rolling back and undermining Obama administration efforts to rein in and reduce greenhouse gas emissions from coal, oil, and auto tailpipes. As of the end of 2019, a New York Times analysis identified 95 environmental rules that are being rolled back by the White House.

A key Trump environmental program roll back is expected to be finalized by the end of March. The administration is relaxing the auto greenhouse gas and fuel economy standards that President Obama announced in 2012. The first national program to reduce transportation greenhouse gas emissions, it was based on science, engineering capabilities, business capacities, as well as environmental and health benefits. It would have doubled fuel economy to 54.5 miles per gallon (mpg) by 2025, eliminated 6 billion tons of carbon dioxide, and saved consumers $1.7 trillion at the pump. It appeared the U.S. was finally listening to climate scientists.

But in early 2017 with Trump at the helm, the auto industry, amidst several years of record sales and profits, found an opportunity to renege on its commitment to the standards and asked the White House to relax the Obama administrations standards. After extensive analysis, the U.S. Environmental Protection Agencys scientists and auto engineers had recently re-affirmed the program. But facts were no longer in control of the process.

The final rule targets the standards for the 2021-2026 period. It is widely expected to pull back the standards to 37 mpg and reduce the annual fuel economy improvement to 1.5%, down from the current 5%.

Here is the rub. Transportation is now the fastest growing sector driving increased U.S. greenhouse gas emissions. Even the Obama administrations standards, which the Trump administration is trying to scale back, were never enough to address this gorilla in the room. A landmark study by the National Academy of Science in 2013 calculated that the worlds entire fleet of vehicles in 2025 would have to average around 180 mpg to limit warming to safe levels. As detailed in my book, Driving the Future, if we achieved the original 2025 target and enacted rules to continue the 5% annual improvement curve through 2050, we would only reach 80% of the target required to meet the Intergovernmental Panel on Climate Changes (IPCC) earlier target of 2C target of safe warming and the gap will be even greater to reach the new IPCC target of 1.5C.

The only pathway to reaching the IPCCs targets is transportation electrification. The administration should abandon the new rules they are developing, leave the current rules in place and begin work on the post 2025 standards. The auto industry has four to five year planning horizons and needs policy certainty. The world needs to avoid the scale of disruptions that climate change will bring even if the slow pace is deceiving.

The current coronavirus crisis has produced one near-miracle: The bitterly partisan U.S. Congress and federal government are quickly negotiating emergency legislation to deal with the public health and economic crises. Hopefully, reliance on science-based health measures will now guide the countrys approach to combatting coronavirus. And, while the world awaits the worst yet to come in coronavirus infections and deaths, the lessons from this pandemic could result in an approach to bi-partisan, scientifically driven commitment to combat climate change.

Like the seemingly insignificant fruit fly, confronting greenhouse gas and fuel economy standards could produce outsized breakthroughs on climate change. Like the coronavirus, listening to scientific warnings about climate change before it is too late could prevent outsized public health and economic tragedies.

And no, this is not a dream. The reality of global disruption is staring us all in the face. Blinking is not an option.

Go here to read the rest:
The Coronavirus Pandemic Shows Us The Importance Of Combatting Climate Change - Forbes

Posted in Human Genetics | Comments Off on The Coronavirus Pandemic Shows Us The Importance Of Combatting Climate Change – Forbes

Coronavirus: Massive gap in US response revealed after scientists learn colleague tested positive through twee – MEAWW

Posted: March 29, 2020 at 4:49 am

Clement Chow, an assistant professor of human genetics at The University of Utah, US, tweeted last week that he was in the ICU with coronavirus. And that's when researchers who had attended a meeting with him found out about it. At a time when experts are stressing on testing and contract tracing to check community transmission, this incident reveals serious and massive gaps in America's fight against COVID-19.

"Hi guys. Have you missed me? Ive been in the ICU fighting...wait for it...Coronavirus! I am the first case at the U of U ICU! Breaking the bamboo ceiling!," tweeted Chow on March 16. He further said, "Basically had a low-grade fever for a few days then a bad cough, that turned into respiratory failure. I came in and they had to put me on high flow oxygen (3 times normal)...hence ICU."

According to a March 20 report in Nature, two dozen geneticists who had attended a meeting with him nine days earlier subsequently saw the tweet and came to know that Chow had tested positive for COVID-19. While the researchers were worried for Chow, they were also upset that this was the first they had heard about it, says the report.

The fact that we learned about this from a tweet points to a failure of our department of health. But maybe we can come together with grass-root responses, Nels Elde, also an associate professor of human genetics at The University of Utah in Salt Lake City, told Nature. He had reportedly shared a dinner plate with Chow before he was diagnosed with COVID-19.

Elde tweeted to Chow on March 16 and said, "Was going through our text messages and your decision to self-quarantine early for cold-like symptoms that you were convinced was not SARS-CoV-2 was a good one and good example for us all. Get well soon @ClementYChow."

Chow further explained that his breathing was so compromised that he could not keep his oxygen levels up even with "10L of oxygen." He said while he was the first COVID19 patient in the ICU on March 19, there are more now. "Important point: we really dont know much about his virus. Im young and not high risk, yet I am in the ICU with a very severe case," said Chow.

Another researcher who had attended the meeting with Chow described how the group from 16 states "scrambled to work out who they had spent time with since returning home from the meeting." "They were upset that four days had passed between when their colleague was hospitalized with symptoms of COVID-19 and when they found out, through Twitter, that he had the disease. Another 24 hours would pass before an email from Utahs public-health departments made it their way. Every passing minute, the virus has a chance to move to someone else," reports Nature.

Meanwhile, the researchers who learned of their exposure through Twitter are taking precautionary measures by taking their temperatures and self-quarantining themselves.

Over 33,270 cases have been reported in the US so far, and 417 have died. New York state accounts for 117 deaths currently, passing Washington state, the initial epicenter of the pandemic in the US, in the number of fatal cases.

According to experts, contact tracing is important as people in close contact with someone who is infected with a virus, such as the COVID-19 virus are at higher risk of becoming infected themselves and of potentially further infecting others.

An analysis of Singapores containment measures that were implemented to minimize disease spread, for example, shows that contact tracing contributed to the primary detection of approximately half (53%) of COVID-19 patients. The study, based on a review of the first 100 cases in Singapore, shows that the mean interval from symptom onset to isolation was 5.6 days and declined after approximately 1 month.

Singapore implemented strong surveillance and containment measures, which appear to have slowed the growth of the outbreak. The study estimated that if other countries had similar detection capacities as Singapore, the global number of imported cases detected would be 2.8 times higher than the observed current number, said the report. It added, The surveillance methods in Singapore complemented one another to identify infected persons, with the overlapping components constituting safety nets; none of the methods alone would have detected all patients.

During a media briefing on March 16, the World Health Organization (WHO) Director-general Dr Tedros Adhanom Ghebreyesus had said that while there has been a rapid escalation in social distancing measures across countries, they have not seen an urgent enough escalation in testing, isolation and contact tracing which, he said, was the backbone of the COVID-19 response. "We have a simple message for all countries: test, test, test, he had emphasized.

Dr Ghebreyesus explained that while social distancing measures can help to reduce transmission and enable health systems to cope, such measures alone would not be enough to "extinguish this pandemic." "Its the combination that makes the difference. As I keep saying, all countries must take a comprehensive approach, he said.

Read the original:
Coronavirus: Massive gap in US response revealed after scientists learn colleague tested positive through twee - MEAWW

Posted in Human Genetics | Comments Off on Coronavirus: Massive gap in US response revealed after scientists learn colleague tested positive through twee – MEAWW

Qatar University’s Biomedical Research Center conducting research on COVID-19 – The Peninsula Qatar

Posted: March 29, 2020 at 4:49 am

29 Mar 2020 - 8:18

Dr. Hadi Yassine, Research Projects Manager at Qatar University's Biomedical Research Center, working in a laboratory.

Qatar Universitys Biomedical Research Center (BRC-QU) in collaboration with external entities initiated several research activities focused on coronavirus (COVID-19 and MERS-CoV) lead by Dr. Asmaa Al Thani, Director at QU Biomedical Research Center and Dr. Hadi Yassine, Research Projects Manager at the Center.BRC initiated many researches to fight the emerging (COVID-19). These six researches included, A detailed analysis of exported COVID-19 cases (from China to the rest of the world) which is being done in collaboration with College of Medicine QU and Ministry of public Health (MoPH); Using digital simulation technology to test the ability of some inhibitors to stop COVID-19 binding to its cellular receptors conducted by BRC; Study of the genetics evolution of seasonal and zoonotic coronavirus that infects humans, a research being made in collaboration between The Biomedical Research Center QU and Hamad bin Khalifa University Qatar Foundation; Study the evolution of the Coronavirus (MERS) that causes respiratory syndrome in humans and camels in the Middle East held by The Biomedical Research Center QU, Hamad Medical Corporation (HMC) and (MoPH); A comparative study on the presence and amount of anti-coronavirus antibodies against seasonal and zoonotic coronaviruses in humans in Qatar Published in February 2, 2019 by The Biomedical Research Center QU and MoPH; and Study on the complete structure of the coronavirus spike protein (viral thorn) its pre-bonding form with cellular receptors, published on March 2, 2016 by the National Institute of Health (USA) and Biomedical Research Center QU.In order to reach the various private and public health sectors in Qatar and to build necessary capacities, the Center, and in collaboration with Hamad Medical Corporation (HMC), Ministry of Public Health (MOPH) and international partners, had organized international workshops and including The Fourth International Conference on Human, Animal and Environment Interaction with Emerging Diseases 2017.The conference was the first of its kind in the region and it has received a wide echoes at the local and international levels, where the number of attendees exceeded 300, including 115 from foreign and Arab countries.It is worth mentioning that the Center for Biomedical Research at QU collaborate with various government institutions in the country not only in research, but also in service and outreaching activities. In terms of research, the Center has participated in several research projects with a number of government health (MOPH, MME, HMC, Qatar foundation and other) on antibiotic profiling of antibiotics resistant microbes in humans and animals (One health approach) and others on several viral infections circulating in Qatar.The Center seeks to engage the various sectors in the country in its research projects. In this respect, the Center has cooperated with the industrial sector in Qatar through a research project with ExxonMobil on the DNA sequence of the Dugong (sea cow). The Center is also cooperating with some community institutions, such as Al Gannas Society in Katara in the project titled Decoding the Genetic Code of Qatari Falcons.One of that the most important achievements of the Center is the establishment of a laboratory that matches the third level of laboratory bio-safety by CERTEK International, - United States of America.The Laboratories that specialize in infectious microbes are classified into four levels of bio-safety (BSL1, 2, 3, 4), based on the risk level of the studied microbes. For example BSL-3 laboratories provide safety factors when dealing with or treating infectious, self or exotic factors that are transmitted by inhalation and can cause serious illness.Examples of these germs are the highly pathogenic influenza viruses (H5N1), coronaviruses (MERS / SARS/ COVID-19), and Mycobacterium tuberculosis (TB). Currently, there is only one BSL3 laboratory in Qatar at Hamad Medical Corporation, which has been mandated to diagnose tuberculosis and its respective research.QUs BRC provides practical and logistical procedures to support medical and biological research at the college levels.

Read the rest here:
Qatar University's Biomedical Research Center conducting research on COVID-19 - The Peninsula Qatar

Posted in Human Genetics | Comments Off on Qatar University’s Biomedical Research Center conducting research on COVID-19 – The Peninsula Qatar

The Agricultural Biotechnology Industry 2020: Emerging Technologies and Global Markets – ResearchAndMarkets.com – Yahoo Finance

Posted: March 29, 2020 at 4:47 am

The "Agricultural Biotechnology: Emerging Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The study scope includes key agricultural biotechnology tools (i.e., next-generation DNA sequencing, biochips, RNA interference, synthetic biology tools, and gene editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

The report analyzes these technologies and products to determine present and future market sizes, and to forecast growth from 2019 through 2024. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status and market driving forces.

The research provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS and microarray companies); major seed companies; biotech trait companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2018 and 2019.

96 agricultural and biotechnology companies are profiled in this report.

The report includes:

Market Insights

Global megatrends are driving the need for higher agricultural yields, creating strong tailwinds for innovative seed traits and biological pesticides and stimulants.

World population growth, coupled with rising incomes, lead to consumption of higher-quality foods, including meat. This, in turn, creates higher consumption of feed crops, including maize, soy, and wheat. At the same time, the total acreage of arable land available for producing crops is under pressure from a range of forces, including growing populations, urbanization, and global warming.

These global forces are creating leverage in the industry to increase productivity and crop yields. Biotechnology provides strategic tools for the agricultural industry to meet these market demands. This report examines the role of these technologies in agriculture and quantifies their market impact.

Reasons for Doing the Study

Agriculture is a fundamental and strategic component of a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields and other desirable traits. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader. The report does this by examining the main product applications and markets, thereby helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments, in order to help the reader better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, gene editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 Agricultural Biotechnology Applications

Chapter 6 DNA Read, Write and Edit Industries

Chapter 7 Acquisitions and Strategic Alliances

Chapter 8 Agricultural Biotechnology Markets

Chapter 9 Patents

Chapter 10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/fwyt4b

View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005159/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

More:
The Agricultural Biotechnology Industry 2020: Emerging Technologies and Global Markets - ResearchAndMarkets.com - Yahoo Finance

Posted in Biotechnology | Comments Off on The Agricultural Biotechnology Industry 2020: Emerging Technologies and Global Markets – ResearchAndMarkets.com – Yahoo Finance

PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update – BioSpace

Posted: March 29, 2020 at 4:47 am

PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotechnology) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune today announced its financial results for the full year ended December 31, 2019 and provided a business update.

Fourth Quarter 2019 and Recent Business Highlights

We have made significant progress over the last year as we transitioned to a public company, strengthened our partnerships with leaders in immuno-oncology, such as Merck and National Cancer Institute and reported encouraging human data from our lead program, PDS0101, commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. As we forge ahead in 2020, we look forward to leveraging the highly encouraging Phase I human clinical outcome data, which demonstrated complete lesion regression in 60% of evaluable patients with cervical intraepithelial neoplasia (CIN) and human papillomavirus (HPV) within 1-3 months of treatment. These results support our combination approach in our upcoming clinical trials and provide evidence that PDS0101 could be essential in expanding the clinical efficacy of checkpoint inhibitors and improving clinical outcomes for patients.

With a strengthened balance sheet, we look forward to initiating three studies, including; a Phase 2 combination study to evaluate PDS0101 in combination with KEYTRUDA in the first line treatment of metastatic head and neck cancer, a Phase 2 study to evaluate PDS0101 in combination with two promising immune-modulating agents in advanced HPV-associated cancers with the NCI and a Phase 2a study to evaluate the combination of PDS0101 and chemoradiation in patients with locally advanced cervical cancer. We remain committed to developing our novel Versamune platform in collaboration with our partners and would like to thank our shareholders for their continued support, concluded Dr. Bedu-Addo.

Full Year 2019 Financial Review

For the year ended December 31, 2019, the net loss was approximately $6.9 million, or $1.44 per basic and diluted share. This compares to a net loss of approximately $3.8 million, or $1.15 per basic and diluted share for the year ended December 31, 2018.

For the year ended December 31, 2019, research and development expenses increased approximately 634% to approximately $6.1 million compared to approximately $0.8 million in the prior year. The increase is primarily attributable to an increase in external expenses for clinical studies, internal R&D personnel costs, non-cash stock-based compensation and departmental costs.

For the year ended December 31, 2019, general and administrative expenses increased approximately 294% to approximately $11.0 million compared to approximately $2.8 million in the prior year. The increase was due to increases in personnel costs, non-cash stock-based compensation, facilities costs, D&O insurance costs, legal fees, professional fees and other operating expenses.

For the year ended December 31, 2019, total operating expenses increased approximately 477% to approximately $21.0 million compared to approximately $3.6 million in the prior year.

As of December 31, 2019, the Companys cash balance was approximately $12.2 million. This amount does not include the approximately $11.9 million in net proceeds after deducting underwriting discounts and commissions, not including other offering expenses from PDS Biotechs underwritten public offering including the full exercise of the underwriters overallotment option, which closed in February.

About PDS Biotechnology

PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotech is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechs pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; potential adverse reactions or changes to business relationships resulting from the resignation of the Companys Chief Financial Officer or the Companys ability to find a replacement Chief Financial Officer; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

(Financial Statements to Follow)

PDS BIOTECHNOLOGY CORPORATION and Subsidiaries

Consolidated Balance Sheets

PDS BIOTECHNOLOGY CORPORATION and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

See original here:
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update - BioSpace

Posted in Biotechnology | Comments Off on PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update – BioSpace

HIPRA makes part of its biotechnology facilities and equipment available to the health authorities – The Poultry Site

Posted: March 29, 2020 at 4:47 am

HIPRA, the multinational Animal Health company, which has its headquarters in Amer (Girona), has reached an agreement with the health authorities that will allow the principal hospitals in the province of Girona to make use of its new facilities (nearly 700 m2 of laboratories equipped with the latest PCR diagnostic technology), thus helping to streamline the management and production of results of tests for coronavirus SARS-CoV-2.

These are facilities that the company had just finished building at its headquarters as part of its business expansion plan and that it was about to open.

As an Animal Health company, for us it is a duty and an act of responsibility to make use of all the resources that we have in order to help preserve public health in such exceptional times, hence the need to collaborate by giving over our new diagnostic centres, the company announced.

The samples received will come from different hospitals in the region and will be processed in accordance with international protocols and the strictest biosecurity and biocontainment measures. Staff from the hospitals, and from various local biotechnology startups who are parties to this agreement, will move to HIPRAs facilities and will be responsible for the entire process of analysis, whilst the companys experts will provide support with their knowledge and experience in biotechnology.

HIPRA develops and sells vaccines for animals, and also provides a variety of services for the prevention and control of various animal diseases on livestock farms. It uses the latest PCR analysis technology for the diagnosis of these diseases.

This type of real-time diagnosis allows hundreds of samples to be analysed in a few hours, backed up by the automation of the process, so we are convinced that this will be of great help explained the company.

It is estimated that this collaboration will last for 2 or 3 weeks and will remain in force for as long as the health authorities need our help in the current health emergency, announced the company.

HIPRA is also producing components for the manufacture of medical ventilators by 3D printing which will also be supplied to hospitals in the region. This project is being co-ordinated through companies and institutions such as HP, LEITAT Managing Technologies and other public bodies.

The company has anticipated and introduced a whole series of measures to preserve the health of its employees and everyone around them. HIPRA is continuing to manufacture and distribute its medicinal products, which is essential both to ensure the supply of healthy food to the population and to maintain the health of our pets who share our homes.

We have a duty to keep up our normal levels of production as we make a vital contribution to the food supply chain and to the health of the population with products that are considered to be basic essentials

Read more from the original source:
HIPRA makes part of its biotechnology facilities and equipment available to the health authorities - The Poultry Site

Posted in Biotechnology | Comments Off on HIPRA makes part of its biotechnology facilities and equipment available to the health authorities – The Poultry Site

2 Biotechnology ETFs That Could Be Good For Diversification – ETF Trends

Posted: March 29, 2020 at 4:47 am

While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making strides might not be such a bad idea.

With the COVID-19 pandemic raging, biotechs that are consistently profitable and that offer drugs that patients absolutely must have could be seen as relatively safe compared to many other stocks on the market. For investors looking to stay in the market and diversify portfolios, here are two biotech ETFs that could be worth diversifying into during the coronavirus crisis.

With biotech companies like Gilead Sciences, which has been in the news a lot recently for the antiviral drug remdesivir, which appears to be the most promising treatment for COVID-19, IBB is a place for biotech investors to consider. Gilead is conducting late-stage studies of the drug and could report initial results as early as April. Gilead also has adividend yield currently stands at nearly 4%. The company has even augmented its dividend by 58% over the last five years.

IBB seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

While the iShares Genomics Immunology and Healthcare ETF has no directly related coronavirus drug-making companies in its holdings, it does contain stocks like Exelixis, which makes drugs that are used to treat kidney, liver, and medullary thyroid cancer, which will continue to be important going forward. The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

For more market trends, visitETF Trends.

See the rest here:
2 Biotechnology ETFs That Could Be Good For Diversification - ETF Trends

Posted in Biotechnology | Comments Off on 2 Biotechnology ETFs That Could Be Good For Diversification – ETF Trends

Biotech and Big Pharma Join Fight Against Covid-19. Why They Need to Do More, – Barron’s

Posted: March 29, 2020 at 4:47 am

Nearly every U.S. industry is struggling with the effects of the pandemic. Only one has a shot at stopping the virus itself.

Over the past decade, biotechnology firms and pharmaceutical companies have stockpiled an armament of scientists, laboratories, and capital in the billions of dollars. Those labs could end the current global nightmare of Covid-19.

Are they doing enough?

Now, after a slow start, there are nearly 60 programs under way to develop a Covid-19 treatment and more than 40 to develop a vaccine, by both commercial and noncommercial labs, according to an accounting by the Milken Institute.

Brian Abrahams, an analyst at RBC Capital Markets, thinks the biotech industry should be doing much more.

We havent seen the broader biotech community come together in a really cohesive way to try to tackle this problem, Abrahams said in an interview on Monday. There are hundreds of companies, tons of talent, and a lot greater understanding of biology and drug discovery than weve ever had.

In recent days, signs of an industrywide movement, like the one Abrahams called for, have begun to emerge, with a biotechnology industry group holding a virtual gathering to coordinate a response.

And generic-drug companies have now rushed to make available a medication that has shown early promise as a Covid-19 therapy.

If youre a mid- or large-cap company, I think its almost a societal duty to be making some effort to leverage whatever expertise you might have.

Its my personal belief that this is the mission of the pharmaceutical industry, says Sol Barer, chairman of the board of Teva Pharmaceutical Industries (ticker: TEVA) and a co-founder of the biotech firm Celgene, which was recently acquired by Bristol-Myers Squibb (BMY). We are here to discover, develop, and commercialize drugs, especially for serious, fatal diseases.

For drugmakers of all types, Covid-19 offers a chance to rehabilitate their image before an American public that has grown increasingly frustrated with high prices and ethical scandals like the opioid crisis and generic-drug price-fixing allegations.

The pharmaceutical industry does have an opportunity here to both help and also to accomplish a very important aspect of rebranding, says Dan Mendelson, founder of Avalere Health, a health-care consulting firm.

It remains unlikely that companies will make money off their Covid-19 programs, but burnishing the industrys image will bring its own value.

Even with no profit motive, says Abrahams, companies should be putting virtually everything aside to work on Covid-19 treatments. If youre a mid- or large-cap company, I think its almost a societal duty to be making some effort to leverage whatever expertise you might have, he says.

Among the Covid-19 research programs in progress are a number of attempts to use messenger RNA to make vaccines that train the body to defend against the virus. Biotech firm Moderna (MRNA) already has an mRNA vaccine in the clinic. BioNTech (BNTX) is working with Pfizer (PFE) and a Chinese company on their own version, Translate Bio (TBIO) is developing one with Sanofi (SNY), and so is the private firm CureVac

Therapeutics under investigation include repurposed antivirals such as Gilead Sciences (GILD) remdesivir and AbbVies (ABBV) Kaletra. Other companies are working on antibody therapies, including Regeneron Pharmaceuticals (REGN) and Vir Biotechnology (VIR), which is teaming up with Biogen (BIIB).

According to Jeremy Levin, CEO of Ovid Therapeutics (OVID) and chairman of the board of the industry group Biotechnology Innovation Organization, or BIO, some 45 biotechs have Covid-19 programs.

Still, that represents only a portion of biotech. Much of the biopharmaceutical industry, like many other industries, has been shut down by the pandemic.

Laboratories are operating with skeleton crews. Companies like Eli Lilly (LLY) and Bristol-Myers have delayed the starts of new drug clinical trials, and armies of salespeople have been effectively grounded. That leaves a lot of capital sitting there while people are dying.

The reality is, from a commercial standpoint, companies with marketed products are not really going to be able to spend the same amount of money on sales costs now, with the country in virtual lockdown, nor will they be able to continue most of their clinical trials until this passes, Abrahams says. Theres a natural bandwidth expansion.

BIOs Levin says that there is a limit to how many biotech companies can tackle Covid-19.

Its very difficult for companies to switch on a dime, he says. If youre a cancer company, its very difficult to switch to being an antiviral company. Half of biotechnology, Levin notes, is focused on cancer.

Still, Levin says, in recent days, the sector has been working to coordinate its Covid-19 response. On Tuesday and Wednesday, BIO organized a virtual summit meant in part to connect the companies working on Covid-19 with government agencies.

From my perspective, theres no one solution, he says. Its a comprehensive Marshall Plan, which goes across all of these companies.

Levin says that one way to bring more companies into the effort is by encouraging collaborations. He highlights an effort by Vir, which focuses on infectious disease, and Alnylam Pharmaceuticals (ALNY), which specializes in a modality called RNA interference, on an RNAi approach to curing Covid-19.

Outside of biotechnology, the pharmaceutical giants have announced their own efforts.

And in a wave this week, generic drugmakers announced plans to ramp up productions of hydroxychloroquine, an antimalarial drug that has shown promise as a Covid-19 treatment. Teva alone donated six million doses of the drug.

The way we can help is, if there are drugs now that are available and generic, we can help supply them in significant quantities, Tevas Barer says. If we make it, we will supply it, we will supply it quickly.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

View post:
Biotech and Big Pharma Join Fight Against Covid-19. Why They Need to Do More, - Barron's

Posted in Biotechnology | Comments Off on Biotech and Big Pharma Join Fight Against Covid-19. Why They Need to Do More, – Barron’s

Page 1,078«..1020..1,0771,0781,0791,080..1,0901,100..»